PFO
KDNY

Pathstone Family Office’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Pathstone Family Office’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-6
Closed – – 676
2017
Q1 		$0 Buy
+6
New +$339 ﹤0.01% 638

Other funds holding KDNY

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Pathstone Family Office's KDNY Position: Q2 2017 in Review

Pathstone Family Office sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2017, closing a stake of 6 shares.

Pathstone Family Office first reported a position in KDNY in Q1 2017 and held it in 1 quarter. The position peaked at $0 in Q1 2017. 82 funds tracked by Wall St. Rank hold KDNY as of Q2 2017.

  • Pathstone Family Office reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Pathstone Family Office sold 6 Chinook Therapeutics, Inc. Common Stock shares in Q2 2017.
  • Pathstone Family Office first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Pathstone Family Office's Chinook Therapeutics, Inc. Common Stock position peaked at $0 in Q1 2017.
  • 82 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Pathstone Family Office's 13F filing for Q2 2017, filed 11 Aug 2017.